We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Research · 10 min read

Estradiol, conjugated estrogens, patch or pill: does the type of hormone therapy matter?

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Hormone therapy comes in more than one form, and new research is asking whether the estrogen type and the route are associated with different findings. Here's what a new brain preprint and a preliminary heart abstract add, and why a product change still belongs with your clinician.

Hormone therapy is not a single medicine. The estrogen may be estradiol or conjugated estrogens. It may be a pill, a patch, a gel, a spray, or a low-dose vaginal product. If you have a uterus and you use systemic estrogen, you typically also need a progestogen. Headlines often talk about "HRT" as if those differences did not exist.

This week, Neuroscience 2026 coverage highlighted research on estrogen type, a common Alzheimer's genetic risk factor, and brain findings, including a University of Toronto–affiliated preprint first posted in September. A preliminary American Heart Association abstract reports similar heart results across oral, patch, and gel therapy. A Canadian decision to stop selling Premarin, alongside patch shortages, is a reminder that knowing how forms differ is a practical skill—not a do-it-yourself project.

Related Kindr reading: estrogen–brain headlines, who should not take hormone therapy, age and timing, and the microbiome and one oral regimen.

The main forms, in plain language

Oral estradiol is a tablet that contains estradiol, the estrogen your ovaries made the most of before menopause. Conjugated estrogens are a mixture of estrogens; Premarin is one well-known brand. Naming a product does not mean Kindr Health prescribes it, or that it is right for you.

Transdermal hormone therapy is absorbed through the skin, as a patch, a gel, or a spray. Low-dose vaginal estrogen—a cream, tablet, or ring—is used for local genitourinary symptoms such as vaginal dryness. It is not the same as systemic therapy for hot flashes. Some systemic product labels say that when the only goal is to treat moderate to severe symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered first.

A progestogen is still typically needed if you have a uterus and use systemic estrogen, to protect the lining of the uterus. That can be a separate tablet, a combined product, or another form your clinician recommends. Local vaginal estrogen is a different situation; whether you also need a progestogen belongs in that visit, not in this article. These products are not interchangeable without clinical guidance.

What a new preprint suggests about estrogen type and APOE4—and what it doesn't

A Society for Neuroscience release, carried on MedicalXpress on November 14, 2026, says research presented at Neuroscience 2026 found that people with a genetic risk for Alzheimer's disease responded differently to menopause hormone therapy than people without that risk, and that the response differed by hormonal formulation. The same release also describes a separate animal study in which memory circuits were especially vulnerable in menopausal rodents with genetic risk for Alzheimer's disease. Animal findings are not human results, and they are not a reason to start or switch therapy.

The human formulation finding matches a medRxiv preprint by Mateja Perović, Liisa A.M. Galea, and colleagues at the Centre for Addiction and Mental Health and the University of Toronto, posted September 20, 2026. It has not been peer-reviewed. The preprint itself says it should not be used to guide clinical practice.

The authors used National Alzheimer's Coordinating Center data from 8,741 cognitively healthy women. Methods include ages 50 to 90. Mean ages at baseline were in the mid-60s to early 70s, depending on the hormone-therapy group. The PubMed/PMC version of the abstract uses the shorthand "older (>70) females," which is tighter than those methods and tabled ages, so this article does not treat "over 70" as the inclusion rule. Most participants were not taking hormone therapy (7,955). Among those who were, the main groups were estradiol alone (414), estradiol plus a progestogen (65), conjugated equine estrogens alone (243), and conjugated equine estrogens plus medroxyprogesterone acetate (64). Route—pill versus patch, for example—was not consistently recorded.

The authors report that associations with thinking-test scores varied by formulation and by test. In the main cognitive models, the differences between APOE4 carriers and non-carriers were not statistically significant; in one sensitivity analysis of a naming task, estradiol looked more favorable for carriers and conjugated equine estrogens for non-carriers. In a brain-imaging subset of 930 participants (59 taking estradiol alone, 871 taking no hormone therapy), APOE4 carriers taking estradiol had more favorable measures—higher volume and cortical thickness, and less white-matter damage—than non-carriers.

That is observational, late-life data, not a randomized trial of starting hormone therapy at menopause to protect the brain. The authors could not consistently account for route, dose, or duration of use, and they lacked detailed reproductive history, including age and type of menopause. This preprint is not evidence that hormone therapy prevents Alzheimer's disease or dementia, and it is not a reason to order an APOE test or switch products on the basis of this paper alone. We made a similar "not prevention" point after earlier estrogen–brain headlines.

A preliminary heart abstract: similar results across oral, patch, and gel

A news release dated November 2, 2026, from the American Heart Association describes an observational analysis of 52,330 women in Israel, ages 45 to 59, with no history of heart disease, blood clots, or cancer. After an average of 12 years, the researchers report similar rates of heart attack, stroke or related heart disease (4.4% with hormone therapy versus 4.6% without), death before age 80 (1.3% versus 1.2%), and blood clots (0.33% in both groups). The release says the results were similar across oral, patch, and gel forms.

This is a research abstract (MDP0654) presented at the American Heart Association's Scientific Sessions 2026. The Association states that abstracts at its meetings are not peer-reviewed and that the findings are preliminary until published as a full paper. The study is observational, so it cannot prove cause and effect. The researchers grouped women by the first type of hormone therapy they used and did not include later switches. It is not a finding that hormone therapy prevents heart disease, and it does not erase known risks in other groups or with other regimens. If you have read our 2026 analysis of starting therapy in perimenopause, treat this as a separate, still-unpublished abstract. The useful point here is the similar pattern across routes—not a green light.

When a product is discontinued or hard to find

On November 12, 2026, CBC News, with Thomson Reuters reporting, said Pfizer will no longer sell Premarin in Canada after an internal review. CBC confirmed that Premarin vaginal cream is currently unavailable there and will not be returning. Pfizer Canada will also no longer market Premarin tablets, though existing tablet inventory is expected to last until about mid-2027 and could run out sooner if demand rises. Pfizer told Reuters the decision was not related to any new safety, efficacy, or quality concerns, that other treatment options remain available in Canada, and that the decision applied only to Canada; the company declined to comment on other markets. The same report says Health Canada has reported certain strengths of estradiol transdermal patches made by Bayer and Sandoz Canada in short supply, with intermittent shortages expected to continue until early 2027.

None of that is a reason to stop, stretch, share, or swap hormone therapy on your own. If you cannot fill a prescription, or you see a headline about a product leaving a market, talk with your clinician and pharmacist. We have previously written about estrogen patch shortages and why a change in form or dose should be a clinical decision.

What the FDA labeling change does—and does not—mean

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. People who have a uterus and use systemic estrogen typically still need a progestogen.

In November 2025, FDA asked manufacturers of menopausal hormone therapies to remove language about cardiovascular diseases, breast cancer, and probable dementia from the boxed warning. FDA's public list of products with updated prescribing information—content current as of October 30, 2026, and unchanged when we rechecked it on November 15, 2026—names nine products. The list page itself does not spell out what changed on each label, and it does not say that boxed-warning statements were removed for those products. We reviewed the nine FDA-approved labels linked from that list, as posted on November 15, 2026; some versions of these labels published elsewhere, including on DailyMed, may not yet reflect every update. On the systemic estrogen-alone products on the list (Divigel, Cenestin, Enjuvia, Minivelle, Vivelle, and Vivelle-Dot), those three topics are no longer in the boxed warning; a boxed warning about endometrial cancer with unopposed estrogen remains. On Bijuva, an estradiol-plus-progesterone capsule indicated for women with a uterus, the boxed warning was removed. The current Prometrium and Estring labels we read do not include a boxed warning. "Removed from the boxed warning" is not "no risks." For systemic products, FDA asked that cardiovascular disease and breast cancer warnings remain in the labeling. See our boxed-warning explainer for what those changes did and didn't do. Hormone therapy also remains contraindicated in specific situations, which we reviewed separately. FDA's labeling request for systemic products also asked companies to add consideration of starting hormone therapy for moderate to severe hot flashes in women younger than 60 or less than 10 years since menopause—guidance about starting, not a stop rule, which we discussed in a recent post.

For people seeking treatment of menopausal vasomotor symptoms—hot flashes and night sweats—the American College of Physicians (ACP) recommends estrogen with a progestogen (for people with a uterus) or estrogen alone (for people without a uterus) as first-line treatment for perimenopausal and postmenopausal people seeking treatment for those symptoms. That is not an automatic yes for every person, and a new preprint or conference abstract should not override a clinician's assessment of benefits, harms, and contraindications. ACP asks clinicians to use informed decision-making and to discuss benefits, harms, contraindications, other conditions, values and preferences, cost, and access.

What is useful to take away now

Ask which product you are on, and why. Estradiol is not the same as conjugated estrogens. A patch is not the same as a pill. A low-dose vaginal product is not the same as systemic therapy for hot flashes. If you have a uterus and use systemic estrogen, a progestogen typically still belongs in the plan.

The new brain paper is a preprint, not a prevention strategy. It is observational, not peer-reviewed, and, in its own words, should not be used to guide clinical practice. It does not show that hormone therapy prevents dementia, and it is not a reason to change products because of APOE4.

The heart abstract is preliminary. Similar event rates across oral, patch, and gel forms are a useful detail, not proof of no risk, and not a reason to start hormone therapy to protect the heart.

If a product is discontinued or in short supply, call your clinician—don't improvise. Switching forms can be appropriate. Doing it without a prescription and a plan is not.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. Conversations about hormone therapy are individualized: your symptoms, your health history, and your goals—including which form may be appropriate if treatment is an option. Kindr Health is a telehealth platform that connects patients with licensed clinicians, who can talk through whether hormone therapy is appropriate for you, what nonhormonal options may be available, and what to do if a product is hard to find. This week's research may help explain why type and route get so much attention. It does not replace a careful visit, and it is not a reason to start, stop, or switch therapy on your own. Kindr Care patient intake is open now.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Sources

Medically reviewed by Kindr Health Clinical Team
Last updated: November 15, 2026

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you

A new JAMA analysis of pharmacy dispensing, as reported by Science News, finds monthly hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, with growth in transdermal and vaginal estrogen while pills stayed flat, and we look at what that means for planning care

Research

Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve

An AMWA position paper names gaps that still keep people from menopause care: training, screening, coverage, research and stigma. We look at what's changing in state law, a new academic post in British Columbia, and ACOG's guidance, and we offer a practical checklist for getting evaluated.

Research

Menopause care is going mainstream in state law: what's changing on coverage, education and work

Statehouses are moving on menopause coverage, education and work: what Illinois has enacted, what is pending in Pennsylvania, and what to ask your insurer. A federal survey also shows how few symptomatic women ages 40 to 60 currently take a prescription, and we look at how ACOG's new guidance fits in.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →